Cargando…

Evacetrapib: in vitro and clinical disposition, metabolism, excretion, and assessment of drug interaction potential with strong CYP3A and CYP2C8 inhibitors

Evacetrapib is an investigational cholesteryl ester transfer protein inhibitor (CETPi) for reduction of risk of major adverse cardiovascular events in patients with high-risk vascular disease. Understanding evacetrapib disposition, metabolism, and the potential for drug–drug interactions (DDI) may h...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cannady, Ellen A, Wang, Ming-Dauh, Friedrich, Stuart, Rehmel, Jessica L F, Yi, Ping, Small, David S, Zhang, Wei, Suico, Jeffrey G
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley & Sons, Ltd 2015
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4618649/ https://www.ncbi.nlm.nih.gov/pubmed/26516590 http://dx.doi.org/10.1002/prp2.179

Ejemplares similares

CYP‐mediated drug–drug interactions with evacetrapib, an investigational CETP inhibitor: in vitro prediction and clinical outcome
por: Cannady, Ellen A., et al.
Publicado: (2015)

Impact of Increased Gastric pH on the Pharmacokinetics of Evacetrapib in Healthy Subjects
por: Small, David S., et al.
Publicado: (2016)

Effects of the cholesteryl ester transfer protein inhibitor evacetrapib on lipoproteins, apolipoproteins and 24-h ambulatory blood pressure in healthy adults
por: Suico, Jeffrey G, et al.
Publicado: (2014)

A Multidose Study to Examine the Effect of Food on Evacetrapib Exposure at Steady State
por: Small, David S., et al.
Publicado: (2015)

Absolute bioavailability of evacetrapib in healthy subjects determined by simultaneous administration of oral evacetrapib and intravenous [(13)C(8)]‐evacetrapib as a tracer
por: Cannady, Ellen A., et al.
Publicado: (2015)

Effect of hepatic or renal impairment on the pharmacokinetics of evacetrapib
por: Small, David S., et al.
Publicado: (2016)

CETP inhibitor evacetrapib enters mouse brain tissue
por: Phénix, Jasmine, et al.
Publicado: (2023)

Effects of Strong CYP2C8 or CYP3A Inhibition and CYP3A Induction on the Pharmacokinetics of Brigatinib, an Oral Anaplastic Lymphoma Kinase Inhibitor, in Healthy Volunteers
por: Tugnait, Meera, et al.
Publicado: (2019)

The Pharmacokinetics and Pharmacokinetic/Pharmacodynamic Relationships of Evacetrapib Administered as Monotherapy or in Combination With Statins
por: Friedrich, S, et al.
Publicado: (2014)

Effect of CETP inhibition with evacetrapib in patients with diabetes mellitus enrolled in the ACCELERATE trial
por: Menon, Venu, et al.
Publicado: (2020)

A PBPK Model to Predict Disposition of CYP3A-Metabolized Drugs in Pregnant Women: Verification and Discerning the Site of CYP3A Induction
por: Ke, A B, et al.
Publicado: (2012)

In vitro and In silico studies of interactions of cathinone with human recombinant cytochrome P450 CYP(1A2), CYP2A6, CYP2B6, CYP2C8, CYP2C19, CYP2E1, CYP2J2, and CYP3A5
por: Lim, Sharoen Yu Ming, et al.
Publicado: (2022)

The Effect of Flavonoid Aglycones on the CYP1A2, CYP2A6, CYP2C8 and CYP2D6 Enzymes Activity
por: Bojić, Mirza, et al.
Publicado: (2019)

Novel Pathways of Ponatinib Disposition Catalyzed By CYP1A1 Involving Generation of Potentially Toxic Metabolites
por: Lin, De, et al.
Publicado: (2017)

Letter to the Editor in Response to “Effect of Polymorphisms in CYP2C9 and CYP2C19 on the Disposition, Safety and Metabolism of Progesterone Administrated Orally or Vaginally”
por: Lazorwitz, Aaron, et al.
Publicado: (2019)

Characterisation of CYP2C8, CYP2C9 and CYP2C19 polymorphisms in a Ghanaian population
por: Kudzi, William, et al.
Publicado: (2009)

Excretion and tissue disposition of dichloroacetonitrile in rats and mice.
por: Roby, M R, et al.
Publicado: (1986)

Strong and Selective Inhibitory Effects of the Biflavonoid Selamariscina A against CYP2C8 and CYP2C9 Enzyme Activities in Human Liver Microsomes
por: Park, So-Young, et al.
Publicado: (2020)

Global variation in CYP2C8–CYP2C9 functional haplotypes
por: Speed, William C, et al.
Publicado: (2009)

CYP2B6*6 Genotype Specific Differences in Artemether‐Lumefantrine Disposition in Healthy Volunteers
por: Abdullahi, Sa'ad T., et al.
Publicado: (2019)

Important Role of CYP2J2 in Protein Kinase Inhibitor Degradation: A Possible Role in Intratumor Drug Disposition and Resistance
por: Narjoz, Céline, et al.
Publicado: (2014)

Author’s Response to: ‘Letter to the Editor in Response to: “Effect of Polymorphisms in CYP2C9 and CYP2C19 on the Disposition, Safety and Metabolism of Progesterone Administrated Orally or Vaginally”’
por: Zubiaur, Pablo, et al.
Publicado: (2019)

CYP2C8 *3 and *4 define CYP2C8 phenotype: An approach with the substrate cinitapride
por: Campodónico, Diana María, et al.
Publicado: (2022)

The pharmacokinetics of pamiparib in the presence of a strong CYP3A inhibitor (itraconazole) and strong CYP3A inducer (rifampin) in patients with solid tumors: an open-label, parallel-group phase 1 study
por: Mu, Song, et al.
Publicado: (2021)

Interactions Among CYP2C8, EPHX2, and CYP4A11 Variants and CYP Plasma Metabolite Levels in Ischemic Stroke
por: Yi, Xingyang, et al.
Publicado: (2016)

Screening of Human CYP1A2 and CYP3A4 Inhibitors from Seaweed In Silico and In Vitro
por: Yim, Sung-Kun, et al.
Publicado: (2020)

A new donors’ CYP3A5 and recipients’ CYP3A4 cluster predicting tacrolimus disposition, and new-onset hypertension in Chinese liver transplant patients
por: Liu, Yuan, et al.
Publicado: (2017)

Effects of rolapitant administered orally on the pharmacokinetics of dextromethorphan (CYP2D6), tolbutamide (CYP2C9), omeprazole (CYP2C19), efavirenz (CYP2B6), and repaglinide (CYP2C8) in healthy subjects
por: Wang, Jing, et al.
Publicado: (2018)

Effect of Chronic Kidney Disease on Nonrenal Elimination Pathways: A Systematic Assessment of CYP1A2, CYP2C8, CYP2C9, CYP2C19, and OATP
por: Tan, Ming‐Liang, et al.
Publicado: (2017)

CYP2C8 and CYP2C9 mRNA expression profile in the human fetus
por: Johansson, Maria, et al.
Publicado: (2014)

Identification and Analysis of CYP7A1, CYP17A1, CYP20A1, CYP27A1 and CYP51A1 in Cynomolgus Macaques
por: UNO, Yasuhiro, et al.
Publicado: (2014)

Polymorphisms in the cytochrome P450 genes CYP1A2, CYP1B1, CYP3A4, CYP3A5, CYP11A1, CYP17A1, CYP19A1 and colorectal cancer risk
por: Bethke, Lara, et al.
Publicado: (2007)

From mRNA Expression of Drug Disposition Genes to In Vivo Assessment of CYP-Mediated Biotransformation during Zebrafish Embryonic and Larval Development
por: Verbueken, Evy, et al.
Publicado: (2018)

CYP2C8 and antimalaria drug efficacy
por: Gil, JP, et al.
Publicado: (2007)

The Effects of H(2)S on the Activities of CYP2B6, CYP2D6, CYP3A4, CYP2C19 and CYP2C9 in Vivo in Rat
por: Wang, Xianqin, et al.
Publicado: (2013)

Enantiomeric Fractions Reveal Differences in the Atropselective Disposition of 2,2′,3,5′,6-Pentachlorobiphenyl (PCB 95) in Wildtype, Cyp2abfgs-Null, and CYP2A6-Humanized Mice
por: Li, Xueshu, et al.
Publicado: (2023)

Interactions of 7,8-Dihydroxyflavone with Serum Albumin as well as with CYP2C9, CYP2C19, CYP3A4, and Xanthine Oxidase Biotransformation Enzymes
por: Fliszár-Nyúl, Eszter, et al.
Publicado: (2019)

The Effects of Weak and Strong CYP3A Induction by Rifampicin on the Pharmacokinetics of Five Progestins and Ethinylestradiol Compared to Midazolam
por: Wiesinger, Herbert, et al.
Publicado: (2020)

Novel structural CYP51 mutation in Trypanosoma cruzi associated with multidrug resistance to CYP51 inhibitors and reduced infectivity
por: Franco, Caio H., et al.
Publicado: (2020)

The clinically relevant CYP2C8*3 and CYP2C9*2 haplotype is inherited from Neandertals
por: Haeggström, Sigrid, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_tdl9fq9e5mqbfemmn89purnbmn